Skip to main content
Matthew Painschab, MD | Institute for Global Health and Infectious Diseases

Matthew Painschab, MD

Assistant Professor of Medicine

Adult Oncology Research

UNC Project Malawi

Mattew-Painschab-IGHID-Profile

Contact Information

Address

Office:
101 Manning Drive
CB#7305
Chapel Hill, NC 27599

Resources

Matthew Painschab, MD

Assistant Professor of Medicine

Adult Oncology Research

UNC Project Malawi

Areas of Interest

Multicentric Castleman Disease, HIV-associated Lymphoma, Kaposi Sarcoma, Viral Oncology, Global Oncology, Data Science and Visualization

About

Dr. Painschab bridges two worlds as a clinician and researcher, treating patients with hematologic malignancies in Chapel Hill and at our partner site in Malawi, UNC Project Malawi. His primary research interest is in HIV-associated cancers, especially virally mediated cancers including multicentric Castleman disease, lymphoma, and Kaposi sarcoma. Dr. Painschab’s research and training are based at our partner site in Malawi, UNC Project Malawi, where he primarily lives. His teaching focus at UNC Project Malawi is on training domestic and international researchers to work in global oncology, with a specific focus on clinical research skills and modern data management and analysis techniques to improve data sharing and research reproducibility.

Memberships:

  • American Society of Hematology
  • American Society of Clinical Oncology
  • African Organization for Research and Training in Cancer

In the news

Education

  • Undergraduate

    University of Minnesota

  • Medical School

    Washington University

  • Residency

    Northwestern University

  • Fellowship

    University of North Carolina at Chapel Hill

InstituteforGlobalHealthandInfectiousDiseases_logo_white_v

 

Bioinformatics Building
130 Mason Farm Rd, 2nd floor
University of North Carolina, Chapel Hill, NC

Tel: 919.966.2537

 

 

MAKE A GIFT

Your gift will advance vital research that can save lives and promote health and well being around the world.

Donate Now

 

Subscribe To:

  • This field is for validation purposes and should be left unchanged.